Key U.S. medical group adds steroids to COVID-19 treatment guidelines

By Deena Beasley (Reuters) - The Infectious Diseases Society of America (IDSA) has updated its treatment guidelines to include generic steroid pills for patients hospitalized with severe COVID-19, the disease caused by the new coronavirus. The only other drug the medical group recommends for COVID-19 patients outside of a clinical trial is remdesivir, the intravenous antiviral medication made by Gilead Sciences Inc.

Reuters June 27, 2020 00:09:18 IST
Key U.S. medical group adds steroids to COVID-19 treatment guidelines

Key US medical group adds steroids to COVID19 treatment guidelines

By Deena Beasley

(Reuters) - The Infectious Diseases Society of America (IDSA) has updated its treatment guidelines to include generic steroid pills for patients hospitalized with severe COVID-19, the disease caused by the new coronavirus.

The only other drug the medical group recommends for COVID-19 patients outside of a clinical trial is remdesivir, the intravenous antiviral medication made by Gilead Sciences Inc.

The IDSA late on Thursday said its change was based on recent data from a United Kingdom study showing that a low-cost and widely used steroid called dexamethasone reduced death rates by around a third among the most severely ill hospitalized COVID-19 patients.

The group now suggests dexamethasone, or an equivalent steroid such as methylprednisolone or prednisone, for hospitalized COVID-19 patients who require supplemental oxygen, mechanical ventilation or extracorporeal mechanical oxygenation (ECMO). The IDSA does not recommend steroids for COVID-19 patients who do not require supplemental oxygen.

In patients with severe COVID-19, the immune system can overreact, triggering a potentially harmful cascade. Steroids are an older class of drugs used to suppress that inflammatory response, but they can also make it easier for other infections to take hold - and doctors are leery of their use in a hospital setting, or in patients in earlier stages of the illness when they body's immune response needs to be on high alert.

The IDSA recommends remdesivir for hospitalized patients with severe COVID-19, but supplies of the antiviral drug are tight. The guidelines note that remdesivir appears to offer the most benefit for patients who need oxygen, but are not on a ventilator or ECMO.

Gilead has not yet set a price for remdesivir, which has been available on a limited basis through company donations, compassionate use requests and clinical trials.

The Institute for Clinical and Economic Review this week suggested a price range for remdesivir of $2,520 to $2,800 per treatment course if dexamethasone becomes a standard treatment for COVID-19. The U.S. price for dexamethasone is around $15 for a 10-day course of treatment.

(Reporting by Deena Beasley; Editing by Tom Brown)

This story has not been edited by Firstpost staff and is generated by auto-feed.

Updated Date:

TAGS:

Find latest and upcoming tech gadgets online on Tech2 Gadgets. Get technology news, gadgets reviews & ratings. Popular gadgets including laptop, tablet and mobile specifications, features, prices, comparison.

also read

EU poised to secure Sanofi deal for coronavirus vaccine
Business

EU poised to secure Sanofi deal for coronavirus vaccine

By Foo Yun Chee BRUSSELS (Reuters) - The European Union's executive on Friday wrapped up preliminary talks with French drugmaker Sanofi aimed at securing its COVID-19 vaccine for the 27-country EU bloc, the latest deal with vaccine producers. Armed with an emergency fund of more than 2 billion euros ($2.4 billion), the European Commission wants to strike deals with up to six drugmakers for their vaccines for their 450 million citizens against the coronavirus that has killed 674,000 people worldwide

U.S. consumer spending presses ahead; declining income poses challenge
Business

U.S. consumer spending presses ahead; declining income poses challenge

By Lucia Mutikani WASHINGTON (Reuters) - U.S. consumer spending increased for a second straight month in June, setting up consumption for a rebound in the third quarter, though the recovery could be limited by a resurgence in COVID-19 cases and the end of expanded unemployment benefits.

U.S. imposes sanctions on Chinese company over abuse of Uighurs
Business

U.S. imposes sanctions on Chinese company over abuse of Uighurs

By Steve Holland and Daphne Psaledakis WASHINGTON (Reuters) - The United States intensified its economic pressure on China's Xinjiang province on Friday, imposing sanctions on a powerful Chinese company and two officials for what it said were human rights abuses against Uighurs and other ethnic minorities. The move, the latest blow to U.S.-China relations, came a week after U.S